Affordable Access

Publisher Website

Infección y pie diabético. ¿Existen nuevas posibilidades terapéuticas?

Authors
Journal
Angiología
0003-3170
Publisher
Elsevier
Volume
58
Issue
5
Identifiers
DOI: 10.1016/s0003-3170(06)74993-8
Keywords
  • Antibióticos
  • Infección
  • Pie Diabético
  • Resistencias
  • Staphylococcus Aureus
  • Antibiotics
  • Diabetic Foot
  • Infection
  • Resistances

Abstract

Summary Introduction One of the most serious aspects of diabetic foot ulcers is infection, since this leads to a poorer prognosis and makes treatment more complicated. Being aware of its severity, early detection of the microorganism causing the infection and determining its antibiogram are priority aspects in the treatment of these patients. The frequent use of antibiotics in patients with diabetic foot makes antimicrobial resistance a factor to be taken into account when it comes to choosing an antibiotic, especially to prevent administration of unsuitable empirical treatment with the increased morbidity and mortality this entails. This has led to research and development of new drugs for the treatment of these infections, as is the case for example of linezolid or ertapenem, which are already on the market, or tigecycline and dalbavancin, which are on their way to being commercialised in the future. Development The role played by these new antibiotics and the impact they have on diabetic foot infections are analysed on the basis of recently reported clinical trials. Conclusions The rational use of the new drugs described here can improve outcomes in cases of diabetic foot infection.

There are no comments yet on this publication. Be the first to share your thoughts.